Evaluation of a Particulate Breast Cancer Vaccine Delivered via Skin

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Breast cancer is a leading global health concern for women, with current treatments having limitations.
• Immunotherapy, particularly vaccines, presents a promising alternative for breast cancer treatment.
• Developing effective and accessible breast cancer vaccines is a critical research area.

Purpose of the Study:

• To evaluate a novel particulate breast cancer vaccine delivered intradermally using microneedles.
• To assess the vaccine's ability to elicit a robust immune response.
• To determine the vaccine's efficacy in suppressing breast cancer tumor growth in vivo.

Main Methods:

• A particulate vaccine was prepared using spray drying with murine breast cancer whole cell lysate.
• The vaccine was administered intradermally via metal microneedles, with microchannel visualization using confocal microscopy.
• Immune responses (serum IgG, IgG2a, CD4+, CD8+ cells) and tumor suppression were measured in vaccinated and control mice.

Main Results:

• Microneedles successfully created microchannels for vaccine delivery to skin layers.
• Vaccinated mice showed significantly higher levels of key immune markers (IgG, IgG2a, B and T cells) compared to controls.
• Vaccinated animals exhibited a five-fold increase in tumor suppression after challenge with live breast cancer cells.

Conclusions:

• The particulate breast cancer vaccine delivered via microneedles effectively activates the immune system and provides significant protection against tumor growth.
• This microneedle-delivered vaccine represents a potential advancement in individualized immunotherapy for breast cancer, particularly post-surgical treatment.
• The findings support further investigation into this approach for prolonging relapse-free intervals in breast cancer patients.